Huntington Disease (HD), commonly known as Huntington’s Chorea, is a genetic disorder that starts as a progressive brain disorder. It results in physical, mental, and psychological symptoms that worsen over time. It is caused by a gene mutation located on the short arm of chromosome 4. It is autosomal, which means it is passed from parent to child and can affect both genders. HD is an incurable, degenerative brain disorder that affects physical and mental abilities. It is characterized by an uncontrolled and jerky movement of the limbs, torso, and face (“chorea”). It also causes cognitive symptom such as changes in mood, thinking, and behavior. Other symptoms may include depression, memory loss, and impaired judgment. The onset of HD typically occurs between the ages of 35 and 50. It is estimated that about 30,000-40,000 people in the United States are living with HD. The disease is usually inherited as an autosomal dominant trait, meaning a single gene mutation passed from parent to child is responsible for the disease. It is estimated that approximately one in 10,000 has Huntington Disease. HD is diagnosed after a physical exam and lab tests such as genetic tests or a CT scan. Treatment is usually focused on controlling the physical, mental, and emotional symptoms. Medications used to treat HD include mood stabilizers, anticonvulsants, and antipsychotics. Psychotherapy can be helpful in managing psychological problems related to HD. HD can be devastating to the individuals affected and their families. The effects of HD may be minimized through lifestyle changes, such as exercise and stress management. Social support systems can be beneficial by providing resources and support for the individuals and families living with HD. Programs such as clinical trials may also provide promising treatments for HD. In conclusion, Huntington Disease is a serious, inherited disorder that affects physical and mental abilities. It has no cure, but treatments can be used to control the physical, mental, and emotional symptoms. It is important to understand the disease and find ways to cope with the changes it brings.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States